Analysts Offer Insights on Healthcare Companies: Actinogen Medical (OtherATGGF) and Vertex Pharmaceuticals (VRTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinogen Medical (ATGGF – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical (ATGGF)
In a report issued on February 11, Shane Storey from Canaccord Genuity maintained a Buy rating on Actinogen Medical, with a price target of A$0.08. The company’s shares closed last Monday at $0.03.
According to TipRanks.com, Storey is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinogen Medical with a $0.06 average price target.
See today’s best-performing stocks on TipRanks >>
Vertex Pharmaceuticals (VRTX)
In a report issued on February 13, Eliana Merle from Barclays maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $607.00. The company’s shares closed last Friday at $491.47.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $548.95, representing a 16.4% upside. In a report issued on February 13, Oppenheimer also upgraded the stock to Buy with a $540.00 price target.
